You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePindolol
Accession NumberDB00960  (APRD00678)
TypeSmall Molecule
GroupsApproved
DescriptionA moderately lipophilic beta blocker (adrenergic beta-antagonists). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
Structure
Thumb
Synonyms
1-(1H-indol-4-Yloxy)-3-(isopropylamino)propan-2-ol
1-(1H-indol-4-Yloxy)-3-(propan-2-ylamino)-propan-2-ol
1-(1H-indol-4-Yloxy)-3-[(1-methylethyl)amino]propan-2-ol
4-(2-Hydroxy-3-isopropylaminopropoxy)-indole
Betapindol
Blockin L
Blocklin L
Blocklin-L
Calvisken
Cardilate
Carvisken
Decreten
Durapindol
Glauco-visken
Pectobloc
Pinbetol
Pindolol
Pindololum
Prinodolol
Pynastin
Visken
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-pindololtablet10 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Dom-pindololtablet15 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Dom-pindololtablet5 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Gen-pindolol Tab 15mgtablet15 mgoralGenpharm Ulc1994-12-312010-08-04Canada
Mylan-pindololtablet10 mgoralMylan Pharmaceuticals Ulc1994-12-312012-10-19Canada
Mylan-pindololtablet5 mgoralMylan Pharmaceuticals Ulc1994-12-312012-10-19Canada
Nu-pindol Tab 10mgtablet10 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Nu-pindol Tab 15mgtablet15 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Nu-pindol Tab 5mgtablet5 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Pindolol-10 Tab 10mgtablet10 mgoralPro Doc Limitee1989-12-31Not applicableCanada
Pindolol-15 Tab 15mgtablet15 mgoralPro Doc Limitee1989-12-312012-07-23Canada
Pindolol-5 Tab 5mgtablet5 mgoralPro Doc Limitee1989-12-31Not applicableCanada
PMS-pindololtablet10 mgoralPharmascience Inc1998-05-28Not applicableCanada
PMS-pindololtablet15 mgoralPharmascience Inc1998-05-28Not applicableCanada
PMS-pindololtablet5 mgoralPharmascience Inc1998-05-28Not applicableCanada
Sandoz-pindololtablet15 mgoralSandoz Canada Incorporated2006-04-07Not applicableCanada
Sandoz-pindololtablet5 mgoralSandoz Canada Incorporated2006-04-07Not applicableCanada
Sandoz-pindololtablet10 mgoralSandoz Canada Incorporated2006-04-07Not applicableCanada
Syn-pindolol Tab 10mgtablet10 mgoralSyncare Pharmaceutical Inc.1989-12-311997-08-11Canada
Syn-pindolol Tab 15mgtablet15 mgoralSyncare Pharmaceutical Inc.1989-12-311997-08-11Canada
Syn-pindolol Tab 5mgtablet5 mgoralSyncare Pharmaceutical Inc.1989-12-311997-08-11Canada
Teva-pindololtablet5 mgoralTeva Canada Limited1990-12-31Not applicableCanada
Teva-pindololtablet10 mgoralTeva Canada Limited1990-12-31Not applicableCanada
Teva-pindololtablet15 mgoralTeva Canada Limited1990-12-31Not applicableCanada
Viskentablet10 mgoralTribute Pharmaceuticals Canada Inc1978-12-31Not applicableCanada
Viskentablet5 mgoralTribute Pharmaceuticals Canada Inc1978-12-31Not applicableCanada
Viskentablet15 mgoralTribute Pharmaceuticals Canada Inc1978-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pindol Tab 10mgtablet10 mgoralApotex Inc1988-12-31Not applicableCanada
Apo-pindol Tab 15mgtablet15 mgoralApotex Inc1988-12-31Not applicableCanada
Apo-pindol Tab 5mgtablet5 mgoralApotex Inc1988-12-31Not applicableCanada
Pindololtablet5 mg/1oralMylan Pharmaceuticals Inc.1992-09-03Not applicableUs
Pindololtablet5 mg/1oralCarilion Materials Management1992-09-03Not applicableUs
Pindololtablet10 mg/1oralMylan Pharmaceuticals Inc.1992-09-03Not applicableUs
Pindololtablet10 mg/1oralCarilion Materials Management1992-09-03Not applicableUs
Pindololtablet5 mg/1oralNostrum Laboratories, Inc.2016-02-01Not applicableUs
Pindololtablet5 mg/1oralSun Pharmaceutical Industries, Inc.1994-01-27Not applicableUs
Pindololtablet10 mg/1oralNostrum Laboratories, Inc.2016-02-01Not applicableUs
Pindololtablet10 mg/1oralSun Pharmaceutical Industries, Inc.1994-01-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetapindolNot Available
Blockin LNot Available
Blocklin LNot Available
CalviskenNot Available
DecretenNot Available
DurapindolNot Available
Glauco-ViskenNot Available
PectoblocNot Available
PinbetolNot Available
PrinodololNot Available
PynastinNot Available
ViskenNot Available
Brand mixtures
NameLabellerIngredients
Viskazide 10/25tabTribute Pharmaceuticals Canada Inc
Viskazide 10/50tabTribute Pharmaceuticals Canada Inc
SaltsNot Available
Categories
UNIIBJ4HF6IU1D
CAS number13523-86-9
WeightAverage: 248.3208
Monoisotopic: 248.152477894
Chemical FormulaC14H20N2O2
InChI KeyInChIKey=JZQKKSLKJUAGIC-UHFFFAOYSA-N
InChI
InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3
IUPAC Name
1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene to form 2,3-benzopyrrole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndoles
Direct ParentIndoles
Alternative Parents
Substituents
  • Indole
  • Alkyl aryl ether
  • Benzenoid
  • Heteroaromatic compound
  • Pyrrole
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.
PharmacodynamicsPindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Mechanism of actionPindolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
Related Articles
AbsorptionRapidly and reproducibly absorbed (bioavailability greater than 95%).
Volume of distribution
  • 2 L/kg
Protein binding40%
Metabolism

Hepatic. In man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates.

Route of eliminationPindolol undergoes extensive metabolism in animals and man. In man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates. About 6% to 9% of an administered intravenous dose is excreted by the bile into the feces.
Half life3 to 4 hours
Clearance
  • 50-300 mL/min [cirrhotic patients]
ToxicityLD50=263 mg/kg (orally in rats). Signs of overdose include excessive bradycardia, cardiac failure, hypotension, and bronchospasm.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Pindolol Action PathwayDrug actionSMP00306
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9951
Blood Brain Barrier+0.6929
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.6667
P-glycoprotein inhibitor INon-inhibitor0.9272
P-glycoprotein inhibitor IINon-inhibitor0.9423
Renal organic cation transporterNon-inhibitor0.8179
CYP450 2C9 substrateNon-substrate0.8315
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.708
CYP450 1A2 substrateNon-inhibitor0.7809
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.5
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8331
Ames testNon AMES toxic0.9218
CarcinogenicityNon-carcinogens0.9367
BiodegradationNot ready biodegradable0.9843
Rat acute toxicity2.9438 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9404
hERG inhibition (predictor II)Non-inhibitor0.5774
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Genpharm pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nostrum laboratories inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral5 mg/1
Tabletoral10 mg
Tabletoral15 mg
Tabletoral5 mg
Tabletoral
Prices
Unit descriptionCostUnit
Visken 15 mg Tablet1.52USD tablet
Visken 10 mg Tablet1.05USD tablet
Pindolol 10 mg tablet1.0USD tablet
Pindolol 5 mg tablet0.73USD tablet
Apo-Pindol 15 mg Tablet0.61USD tablet
Gen-Pindolol 15 mg Tablet0.61USD tablet
Novo-Pindol 15 mg Tablet0.61USD tablet
Nu-Pindol 15 mg Tablet0.61USD tablet
Pms-Pindolol 15 mg Tablet0.61USD tablet
Sandoz Pindolol 15 mg Tablet0.61USD tablet
Visken 5 mg Tablet0.61USD tablet
Apo-Pindol 10 mg Tablet0.42USD tablet
Gen-Pindolol 10 mg Tablet0.42USD tablet
Novo-Pindol 10 mg Tablet0.42USD tablet
Nu-Pindol 10 mg Tablet0.42USD tablet
Pms-Pindolol 10 mg Tablet0.42USD tablet
Sandoz Pindolol 10 mg Tablet0.42USD tablet
Apo-Pindol 5 mg Tablet0.24USD tablet
Gen-Pindolol 5 mg Tablet0.24USD tablet
Novo-Pindol 5 mg Tablet0.24USD tablet
Nu-Pindol 5 mg Tablet0.24USD tablet
Pms-Pindolol 5 mg Tablet0.24USD tablet
Sandoz Pindolol 5 mg Tablet0.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point171 °CPhysProp
water solubility7880 mg/LNot Available
logP1.75SANGSTER (1994)
Caco2 permeability-4.78ADME Research, USCD
pKa9.25SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.861 mg/mLALOGPS
logP2.17ALOGPS
logP1.69ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area57.28 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity71.46 m3·mol-1ChemAxon
Polarizability28.27 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.77 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US3471515
General ReferencesNot Available
External Links
ATC CodesC07AA03C07CA03
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.7 KB)
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Pindolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Pindolol.
AbirateroneThe metabolism of Pindolol can be decreased when combined with Abiraterone.
AcebutololPindolol may increase the hypotensive activities of Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Pindolol.
AcepromazineAcepromazine may increase the hypotensive activities of Pindolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Pindolol.
AcetohexamidePindolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Pindolol is combined with Acetylcholine.
AcetyldigitoxinPindolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Pindolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Pindolol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Pindolol.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pindolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Pindolol.
AlfuzosinPindolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Pindolol.
AliskirenPindolol may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Pindolol.
AmbenoniumAmbenonium may increase the bradycardic activities of Pindolol.
AmbrisentanPindolol may increase the hypotensive activities of Ambrisentan.
AmifostinePindolol may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Pindolol.
AminophyllinePindolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Pindolol.
AmlodipineAmlodipine may increase the hypotensive activities of Pindolol.
AmobarbitalAmobarbital may increase the hypotensive activities of Pindolol.
AmodiaquineThe metabolism of Pindolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Pindolol can be increased when it is combined with Amoxapine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Pindolol is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Pindolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Pindolol.
ApraclonidineThe risk or severity of adverse effects can be increased when Pindolol is combined with Apraclonidine.
ApremilastApremilast may decrease the antihypertensive activities of Pindolol.
ArbutaminePindolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Pindolol is combined with Arecoline.
ArformoterolPindolol may decrease the bronchodilatory activities of Arformoterol.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Pindolol.
AripiprazoleAripiprazole may increase the hypotensive activities of Pindolol.
ArtemetherThe metabolism of Pindolol can be decreased when combined with Artemether.
AtenololAtenolol may increase the hypotensive activities of Pindolol.
AtomoxetineThe metabolism of Pindolol can be decreased when combined with Atomoxetine.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Pindolol.
AzelastineAzelastine may decrease the antihypertensive activities of Pindolol.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Pindolol is combined with Azilsartan medoxomil.
BalsalazideBalsalazide may decrease the antihypertensive activities of Pindolol.
BambuterolPindolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalBarbital may increase the hypotensive activities of Pindolol.
BenazeprilBenazepril may increase the hypotensive activities of Pindolol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Pindolol.
BenmoxinBenmoxin may increase the hypotensive activities of Pindolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Pindolol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.
BepridilPindolol may increase the hypotensive activities of Bepridil.
BeractantPindolol may increase the bradycardic activities of Beractant.
BetaxololBetaxolol may increase the hypotensive activities of Pindolol.
BethanecholThe risk or severity of adverse effects can be increased when Pindolol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Pindolol.
BimatoprostBimatoprost may increase the hypotensive activities of Pindolol.
BisoprololBisoprolol may increase the hypotensive activities of Pindolol.
BosentanBosentan may increase the hypotensive activities of Pindolol.
BretyliumBretylium may increase the bradycardic activities of Pindolol.
BretyliumPindolol may increase the hypotensive activities of Bretylium.
BrimonidinePindolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Pindolol.
BromfenacBromfenac may decrease the antihypertensive activities of Pindolol.
BromocriptinePindolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Pindolol.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pindolol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Pindolol.
BupranololPindolol may increase the hypotensive activities of Bupranolol.
BupropionThe metabolism of Pindolol can be decreased when combined with Bupropion.
CabergolinePindolol may increase the vasoconstricting activities of Cabergoline.
CalfactantPindolol may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Pindolol is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Pindolol.
CandoxatrilCandoxatril may increase the hypotensive activities of Pindolol.
CaptoprilPindolol may increase the hypotensive activities of Captopril.
CarbacholThe risk or severity of adverse effects can be increased when Pindolol is combined with Carbachol.
CaroxazoneCaroxazone may increase the hypotensive activities of Pindolol.
CarprofenCarprofen may decrease the antihypertensive activities of Pindolol.
CarteololCarteolol may increase the hypotensive activities of Pindolol.
CarvedilolPindolol may increase the hypotensive activities of Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Pindolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Pindolol.
CeliprololCeliprolol may increase the hypotensive activities of Pindolol.
CeliprololPindolol may decrease the bronchodilatory activities of Celiprolol.
CeritinibPindolol may increase the bradycardic activities of Ceritinib.
CevimelineThe risk or severity of adverse effects can be increased when Pindolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Pindolol.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Pindolol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Pindolol.
ChlorpropamidePindolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Pindolol.
CholecalciferolThe metabolism of Pindolol can be decreased when combined with Cholecalciferol.
CilazaprilPindolol may increase the hypotensive activities of Cilazapril.
CimetidineThe metabolism of Pindolol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Pindolol can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Pindolol can be decreased when combined with Citalopram.
ClemastineThe metabolism of Pindolol can be decreased when combined with Clemastine.
ClenbuterolPindolol may decrease the bronchodilatory activities of Clenbuterol.
ClevidipineThe risk or severity of adverse effects can be increased when Pindolol is combined with Clevidipine.
ClobazamThe metabolism of Pindolol can be decreased when combined with Clobazam.
ClomipramineThe serum concentration of Pindolol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Pindolol.
ClonixinClonixin may decrease the antihypertensive activities of Pindolol.
ClotrimazoleThe metabolism of Pindolol can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Pindolol can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Pindolol can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Pindolol can be decreased when combined with Cocaine.
CoumaphosCoumaphos may increase the bradycardic activities of Pindolol.
CrizotinibPindolol may increase the bradycardic activities of Crizotinib.
CryptenamineCryptenamine may increase the hypotensive activities of Pindolol.
CyclothiazideCyclothiazide may increase the hypotensive activities of Pindolol.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Pindolol.
DapagliflozinThe risk or severity of adverse effects can be increased when Pindolol is combined with Dapagliflozin.
DapoxetineThe serum concentration of Pindolol can be increased when it is combined with Dapoxetine.
DarifenacinThe metabolism of Pindolol can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Pindolol can be increased when it is combined with Darunavir.
DebrisoquinPindolol may increase the hypotensive activities of Debrisoquin.
DecamethoniumDecamethonium may increase the bradycardic activities of Pindolol.
DelavirdineThe metabolism of Pindolol can be decreased when combined with Delavirdine.
DemecariumDemecarium may increase the bradycardic activities of Pindolol.
DeserpidinePindolol may increase the hypotensive activities of Deserpidine.
DesipramineThe metabolism of Pindolol can be decreased when combined with Desipramine.
DeslanosidePindolol may increase the bradycardic activities of Deslanoside.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pindolol.
DiazoxideDiazoxide may increase the hypotensive activities of Pindolol.
DichlorvosDichlorvos may increase the bradycardic activities of Pindolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Pindolol.
DiclofenamideThe risk or severity of adverse effects can be increased when Pindolol is combined with Diclofenamide.
DiflunisalDiflunisal may decrease the antihypertensive activities of Pindolol.
DigitoxinPindolol may increase the bradycardic activities of Digitoxin.
DigoxinPindolol may increase the bradycardic activities of Digoxin.
DihydroergotaminePindolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Pindolol.
DiltiazemDiltiazem may increase the hypotensive activities of Pindolol.
DinutuximabThe risk or severity of adverse effects can be increased when Pindolol is combined with Dinutuximab.
DiphenhydramineThe metabolism of Pindolol can be decreased when combined with Diphenhydramine.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Pindolol.
DipivefrinPindolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Pindolol.
DipyridamoleThe risk or severity of adverse effects can be increased when Pindolol is combined with Dipyridamole.
DisopyramideDisopyramide may increase the bradycardic activities of Pindolol.
DobutaminePindolol may decrease the bronchodilatory activities of Dobutamine.
DonepezilDonepezil may increase the bradycardic activities of Pindolol.
DorzolamideDorzolamide may increase the hypotensive activities of Pindolol.
DoxazosinDoxazosin may increase the hypotensive activities of Pindolol.
DronedaronePindolol may increase the bradycardic activities of Dronedarone.
DroxicamDroxicam may decrease the antihypertensive activities of Pindolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Pindolol.
DroxidopaPindolol may decrease the bronchodilatory activities of Droxidopa.
DuloxetinePindolol may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Pindolol can be decreased when combined with Duloxetine.
DyphyllinePindolol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Pindolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Pindolol.
EfonidipinePindolol may increase the hypotensive activities of Efonidipine.
EliglustatThe metabolism of Pindolol can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Pindolol is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Pindolol.
EnalaprilatPindolol may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Pindolol.
EphedraPindolol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Pindolol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Pindolol.
EpinephrinePindolol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Pindolol.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Pindolol.
EpoprostenolPindolol may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Pindolol.
Ergoloid mesylatePindolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovinePindolol may increase the vasoconstricting activities of Ergonovine.
ErgotaminePindolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Pindolol.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Pindolol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pindolol.
EtanerceptEtanercept may decrease the antihypertensive activities of Pindolol.
EtodolacEtodolac may decrease the antihypertensive activities of Pindolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Pindolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Pindolol.
EtoperidoneThe serum concentration of Pindolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Pindolol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Pindolol.
exisulindexisulind may decrease the antihypertensive activities of Pindolol.
FelodipinePindolol may increase the hypotensive activities of Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Pindolol.
FenfluramineThe serum concentration of Pindolol can be increased when it is combined with Fenfluramine.
FenoldopamFenoldopam may increase the hypotensive activities of Pindolol.
FenoprofenFenoprofen may decrease the antihypertensive activities of Pindolol.
FenoterolPindolol may decrease the bronchodilatory activities of Fenoterol.
FenthionFenthion may increase the bradycardic activities of Pindolol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pindolol.
FingolimodPindolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pindolol.
FlunixinFlunixin may decrease the antihypertensive activities of Pindolol.
FluoxetineThe serum concentration of Pindolol can be increased when it is combined with Fluoxetine.
FluphenazineFluphenazine may increase the hypotensive activities of Pindolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Pindolol.
FluvoxamineThe metabolism of Pindolol can be decreased when combined with Fluvoxamine.
FormoterolPindolol may decrease the bronchodilatory activities of Formoterol.
FosinoprilFosinopril may increase the hypotensive activities of Pindolol.
FurazolidoneFurazolidone may increase the hypotensive activities of Pindolol.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Pindolol.
GalantamineGalantamine may increase the bradycardic activities of Pindolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Pindolol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Pindolol.
GlibornuridePindolol may increase the hypoglycemic activities of Glibornuride.
GliclazidePindolol may increase the hypoglycemic activities of Gliclazide.
GlimepiridePindolol may increase the hypoglycemic activities of Glimepiride.
GlipizidePindolol may increase the hypoglycemic activities of Glipizide.
GliquidonePindolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepidePindolol may increase the hypoglycemic activities of Glisoxepide.
GlyburidePindolol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Pindolol is combined with GTS-21.
GuanabenzGuanabenz may increase the hypotensive activities of Pindolol.
GuanadrelGuanadrel may increase the hypotensive activities of Pindolol.
GuanethidinePindolol may increase the hypotensive activities of Guanethidine.
GuanfacinePindolol may increase the hypotensive activities of Guanfacine.
HaloperidolThe metabolism of Pindolol can be decreased when combined with Haloperidol.
HexamethoniumPindolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Pindolol.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Pindolol.
Huperzine AHuperzine A may increase the bradycardic activities of Pindolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Pindolol.
HydralazinePindolol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazidePindolol may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Pindolol.
HydroxychloroquineThe metabolism of Pindolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Pindolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Pindolol.
IcatibantIcatibant may decrease the antihypertensive activities of Pindolol.
IloprostIloprost may increase the hypotensive activities of Pindolol.
ImipramineThe metabolism of Pindolol can be decreased when combined with Imipramine.
IndacaterolPindolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe serum concentration of Pindolol can be increased when it is combined with Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Pindolol.
IndenololPindolol may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Pindolol can be decreased when combined with Indinavir.
IndomethacinIndomethacin may decrease the antihypertensive activities of Pindolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Pindolol.
IndoraminPindolol may increase the hypotensive activities of Indoramin.
Insulin PorkPindolol may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypotensive activities of Pindolol.
IproniazidIproniazid may increase the hypotensive activities of Pindolol.
IrbesartanPindolol may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Pindolol.
IsoetarinePindolol may decrease the bronchodilatory activities of Isoetarine.
IsoflurophateIsoflurophate may increase the bradycardic activities of Pindolol.
IsoniazidThe metabolism of Pindolol can be decreased when combined with Isoniazid.
IsoprenalinePindolol may decrease the bronchodilatory activities of Isoprenaline.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Pindolol.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Pindolol is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the antihypertensive activities of Pindolol.
IsoxsuprineThe risk or severity of adverse effects can be increased when Pindolol is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Pindolol.
IvabradinePindolol may increase the bradycardic activities of Ivabradine.
KebuzoneKebuzone may decrease the antihypertensive activities of Pindolol.
KetoconazoleThe metabolism of Pindolol can be decreased when combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Pindolol.
KetorolacKetorolac may decrease the antihypertensive activities of Pindolol.
LabetalolLabetalol may increase the hypotensive activities of Pindolol.
LacidipinePindolol may increase the hypotensive activities of Lacidipine.
LacosamidePindolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotidePindolol may increase the bradycardic activities of Lanreotide.
LatanoprostLatanoprost may increase the hypotensive activities of Pindolol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Pindolol.
LercanidipineLercanidipine may increase the hypotensive activities of Pindolol.
LevobunololThe risk or severity of adverse effects can be increased when Pindolol is combined with Levobunolol.
LevodopaPindolol may increase the orthostatic hypotensive activities of Levodopa.
LevomilnacipranThe serum concentration of Pindolol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Pindolol.
LisinoprilLisinopril may increase the hypotensive activities of Pindolol.
LobelineThe risk or severity of adverse effects can be increased when Pindolol is combined with Lobeline.
LofexidinePindolol may increase the hypotensive activities of Lofexidine.
LopinavirThe metabolism of Pindolol can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Pindolol can be decreased when combined with Lorcaserin.
LornoxicamLornoxicam may decrease the antihypertensive activities of Pindolol.
LosartanLosartan may increase the hypotensive activities of Pindolol.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Pindolol.
Lu AA21004The serum concentration of Pindolol can be increased when it is combined with Lu AA21004.
LucinactantPindolol may increase the bradycardic activities of Lucinactant.
LumefantrineThe metabolism of Pindolol can be decreased when combined with Lumefantrine.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Pindolol.
MacitentanPindolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Pindolol.
MalathionMalathion may increase the bradycardic activities of Pindolol.
ManidipinePindolol may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Pindolol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Pindolol.
MebanazineMebanazine may increase the hypotensive activities of Pindolol.
MecamylamineMecamylamine may increase the hypotensive activities of Pindolol.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Pindolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Pindolol.
MefloquineMefloquine may increase the bradycardic activities of Pindolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Pindolol.
MemantineMemantine may increase the bradycardic activities of Pindolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Pindolol.
MesalazineMesalazine may decrease the antihypertensive activities of Pindolol.
MesoridazineMesoridazine may increase the hypotensive activities of Pindolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Pindolol.
MethacholineThe risk or severity of adverse effects can be increased when Pindolol is combined with Methacholine.
MethadoneThe metabolism of Pindolol can be decreased when combined with Methadone.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Pindolol.
MethohexitalMethohexital may increase the hypotensive activities of Pindolol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Pindolol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pindolol.
MethyldopaPindolol may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Pindolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Pindolol.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Pindolol.
MetipranololPindolol may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Pindolol.
MetoprololMetoprolol may increase the hypotensive activities of Pindolol.
MibefradilPindolol may increase the hypotensive activities of Mibefradil.
MidodrinePindolol may increase the bradycardic activities of Midodrine.
MilnacipranThe serum concentration of Pindolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Pindolol.
MinoxidilMinoxidil may increase the hypotensive activities of Pindolol.
MirabegronThe metabolism of Pindolol can be decreased when combined with Mirabegron.
MoclobemideMoclobemide may increase the hypotensive activities of Pindolol.
MoexiprilMoexipril may increase the hypotensive activities of Pindolol.
MolsidomineMolsidomine may increase the hypotensive activities of Pindolol.
MoricizineMoricizine may increase the hypotensive activities of Pindolol.
MoxonidinePindolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Pindolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Pindolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Pindolol.
NadololPindolol may increase the hypotensive activities of Nadolol.
NaftifineNaftifine may decrease the antihypertensive activities of Pindolol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Pindolol.
NaproxenNaproxen may decrease the antihypertensive activities of Pindolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Pindolol.
NebivololPindolol may increase the hypotensive activities of Nebivolol.
NeostigmineNeostigmine may increase the bradycardic activities of Pindolol.
NepafenacNepafenac may decrease the antihypertensive activities of Pindolol.
NesiritideThe risk or severity of adverse effects can be increased when Pindolol is combined with Nesiritide.
NevirapineThe metabolism of Pindolol can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Pindolol.
NicardipineNicardipine may increase the hypotensive activities of Pindolol.
NicorandilNicorandil may increase the hypotensive activities of Pindolol.
NicotineThe risk or severity of adverse effects can be increased when Pindolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Pindolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Pindolol.
NifedipineThe risk or severity of adverse effects can be increased when Pindolol is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Pindolol.
NiguldipinePindolol may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Pindolol can be decreased when combined with Nilotinib.
NilvadipinePindolol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Pindolol.
NimodipineNimodipine may increase the hypotensive activities of Pindolol.
NisoldipineNisoldipine may increase the hypotensive activities of Pindolol.
NitrendipinePindolol may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Pindolol.
NitroprussideNitroprusside may increase the hypotensive activities of Pindolol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Pindolol.
NorepinephrinePindolol may decrease the bronchodilatory activities of Norepinephrine.
ObinutuzumabPindolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Pindolol.
OctreotideOctreotide may increase the bradycardic activities of Pindolol.
OlanzapineThe serum concentration of Pindolol can be increased when it is combined with Olanzapine.
OlmesartanOlmesartan may increase the hypotensive activities of Pindolol.
OlodaterolPindolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Pindolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Pindolol.
OmapatrilatOmapatrilat may increase the hypotensive activities of Pindolol.
OrciprenalinePindolol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Pindolol.
OuabainPindolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Pindolol.
OxprenololPindolol may increase the hypotensive activities of Oxprenolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Pindolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Pindolol.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Pindolol.
PanobinostatThe metabolism of Pindolol can be decreased when combined with Panobinostat.
PapaverineThe risk or severity of adverse effects can be increased when Pindolol is combined with Papaverine.
ParecoxibParecoxib may decrease the antihypertensive activities of Pindolol.
PargylinePindolol may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Pindolol can be increased when it is combined with Paroxetine.
PasireotidePindolol may increase the bradycardic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Pindolol can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololPindolol may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Pindolol.
PentoliniumPindolol may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Pindolol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Pindolol.
PerindoprilPerindopril may increase the hypotensive activities of Pindolol.
PerphenazinePerphenazine may increase the hypotensive activities of Pindolol.
PhenelzinePhenelzine may increase the hypotensive activities of Pindolol.
PheniprazinePheniprazine may increase the hypotensive activities of Pindolol.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Pindolol.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Pindolol.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Pindolol.
PhentolaminePhentolamine may increase the hypotensive activities of Pindolol.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Pindolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Pindolol.
PhenylpropanolaminePindolol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhysostigminePhysostigmine may increase the bradycardic activities of Pindolol.
PilocarpineThe risk or severity of adverse effects can be increased when Pindolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Pindolol.
PinacidilPindolol may increase the hypotensive activities of Pinacidil.
PirbuterolPindolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Pindolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Pindolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Pindolol.
PolythiazidePindolol may increase the hypotensive activities of Polythiazide.
Poractant alfaPindolol may increase the bradycardic activities of Poractant alfa.
PrazosinPrazosin may increase the hypotensive activities of Pindolol.
PrimaquineThe metabolism of Pindolol can be decreased when combined with Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Pindolol.
ProcaterolPindolol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Pindolol.
PromazinePromazine may increase the hypotensive activities of Pindolol.
PromethazinePromethazine may increase the hypotensive activities of Pindolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Pindolol.
PropafenoneThe serum concentration of Pindolol can be increased when it is combined with Propafenone.
PropafenonePindolol may increase the bradycardic activities of Propafenone.
PropranololPropranolol may increase the hypotensive activities of Pindolol.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Pindolol.
PTC299PTC299 may decrease the antihypertensive activities of Pindolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Pindolol.
QuetiapineThe risk or severity of adverse effects can be increased when Pindolol is combined with Quetiapine.
QuinaprilQuinapril may increase the hypotensive activities of Pindolol.
QuinidineThe metabolism of Pindolol can be decreased when combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Pindolol.
RamiprilRamipril may increase the hypotensive activities of Pindolol.
RanolazineThe metabolism of Pindolol can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Pindolol.
RegorafenibRegorafenib may increase the bradycardic activities of Pindolol.
RemikirenRemikiren may increase the hypotensive activities of Pindolol.
RescinnaminePindolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Pindolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Pindolol.
RiociguatPindolol may increase the hypotensive activities of Riociguat.
RisperidonePindolol may increase the hypotensive activities of Risperidone.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Pindolol.
RitodrinePindolol may decrease the bronchodilatory activities of Ritodrine.
RitonavirThe metabolism of Pindolol can be decreased when combined with Ritonavir.
RituximabPindolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Pindolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Pindolol.
RolapitantThe metabolism of Pindolol can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Pindolol can be decreased when combined with Ropinirole.
RuxolitinibRuxolitinib may increase the bradycardic activities of Pindolol.
SafrazineSafrazine may increase the hypotensive activities of Pindolol.
SalbutamolPindolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Pindolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Pindolol.
SalmeterolPindolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Pindolol.
SaprisartanPindolol may increase the hypotensive activities of Saprisartan.
SecobarbitalSecobarbital may increase the hypotensive activities of Pindolol.
SelegilineSelegiline may increase the hypotensive activities of Pindolol.
SelexipagPindolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Pindolol.
SertralineThe serum concentration of Pindolol can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Pindolol.
SilodosinPindolol may increase the orthostatic hypotensive activities of Silodosin.
SitaxentanPindolol may increase the hypotensive activities of Sitaxentan.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Pindolol.
SpiraprilPindolol may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Pindolol.
SRT501SRT501 may decrease the antihypertensive activities of Pindolol.
StiripentolThe metabolism of Pindolol can be decreased when combined with Stiripentol.
SufentanilSufentanil may increase the bradycardic activities of Pindolol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Pindolol.
SulindacSulindac may decrease the antihypertensive activities of Pindolol.
SuprofenSuprofen may decrease the antihypertensive activities of Pindolol.
TacrineTacrine may increase the bradycardic activities of Pindolol.
TadalafilTadalafil may increase the antihypertensive activities of Pindolol.
TamsulosinPindolol may increase the orthostatic hypotensive activities of Tamsulosin.
TelmisartanPindolol may increase the hypotensive activities of Telmisartan.
TemocaprilPindolol may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the antihypertensive activities of Pindolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Pindolol.
TerazosinThe risk or severity of adverse effects can be increased when Pindolol is combined with Terazosin.
TerbinafineThe metabolism of Pindolol can be decreased when combined with Terbinafine.
TerbutalinePindolol may decrease the bronchodilatory activities of Terbutaline.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Pindolol.
TerlipressinPindolol may increase the hypotensive activities of Terlipressin.
TheophyllinePindolol may decrease the bronchodilatory activities of Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Pindolol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Pindolol.
ThiopentalThiopental may increase the hypotensive activities of Pindolol.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pindolol.
ThioridazineThioridazine may increase the hypotensive activities of Pindolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Pindolol.
TibolonePindolol may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Pindolol can be decreased when combined with Ticlopidine.
TicrynafenPindolol may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Pindolol.
TipranavirThe metabolism of Pindolol can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pindolol.
TofacitinibTofacitinib may increase the bradycardic activities of Pindolol.
TolazamidePindolol may increase the hypoglycemic activities of Tolazamide.
TolazolineTolazoline may increase the hypotensive activities of Pindolol.
TolbutamidePindolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Pindolol.
TolmetinTolmetin may decrease the antihypertensive activities of Pindolol.
ToloxatoneToloxatone may increase the hypotensive activities of Pindolol.
TorasemideTorasemide may increase the hypotensive activities of Pindolol.
TrandolaprilTrandolapril may increase the hypotensive activities of Pindolol.
TranilastTranilast may decrease the antihypertensive activities of Pindolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pindolol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Pindolol.
TravoprostTravoprost may increase the hypotensive activities of Pindolol.
TrazodoneThe serum concentration of Pindolol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Pindolol.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Pindolol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Pindolol.
TrichlormethiazidePindolol may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Pindolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Pindolol.
TrimazosinPindolol may increase the hypotensive activities of Trimazosin.
TrimethaphanPindolol may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Pindolol.
TubocurarineTubocurarine may increase the bradycardic activities of Pindolol.
UdenafilUdenafil may increase the antihypertensive activities of Pindolol.
UnoprostonePindolol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Pindolol.
ValsartanValsartan may increase the hypotensive activities of Pindolol.
VardenafilVardenafil may increase the antihypertensive activities of Pindolol.
VareniclineThe risk or severity of adverse effects can be increased when Pindolol is combined with Varenicline.
VenlafaxineThe metabolism of Pindolol can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Pindolol.
VilanterolPindolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe serum concentration of Pindolol can be increased when it is combined with Vilazodone.
VortioxetineThe serum concentration of Pindolol can be increased when it is combined with Vortioxetine.
XylometazolinePindolol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Pindolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Pindolol.
ZileutonZileuton may decrease the antihypertensive activities of Pindolol.
ZimelidineThe serum concentration of Pindolol can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Pindolol can be decreased when combined with Ziprasidone.
ZomepiracZomepirac may decrease the antihypertensive activities of Pindolol.
Food Interactions
  • Magnesium, potassium and zinc needs increased.
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, Kaumann AJ: Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):496-503. Epub 2003 Nov 8. [PubMed:14608456 ]
  3. Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77. [PubMed:1687398 ]
  4. Berendsen HH, Broekkamp CL, Van Delft AM: Antagonism of 8-OH-DPAT-induced behaviour in rats. Eur J Pharmacol. 1990 Oct 2;187(1):97-103. [PubMed:2148726 ]
  5. Watkins DJ, Lawrence AJ, Lewis SJ, Jarrott B: Loss of [125I]-pindolol binding to beta-adrenoceptors on rat nodose ganglion after chronic isoprenaline treatment. J Auton Nerv Syst. 1996 Aug 27;60(1-2):12-6. [PubMed:8884690 ]
  6. Brodde OE, Michel MC, Wang XL, Zerkowski HR: Chronic beta-adrenoceptor antagonist treatment modulates human cardiac and vascular beta-adrenoceptor density in a subtype-selective fashion. J Hypertens Suppl. 1988 Dec;6(4):S497-500. [PubMed:2907348 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
partial agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Rubenstein LA, Zauhar RJ, Lanzara RG: Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation. J Mol Graph Model. 2006 Dec;25(4):396-409. Epub 2006 Mar 30. [PubMed:16574446 ]
  2. Dejgaard A, Liggett SB, Christensen NJ, Cryer PE, Hilsted J: Adrenergic receptors are a fallible index of adrenergic denervation hypersensitivity. Scand J Clin Lab Invest. 1991 Dec;51(8):659-66. [PubMed:1666931 ]
  3. Wheeldon NM, Newnham DM, Fraser GC, McDevitt DG, Lipworth BJ: The effect of pindolol on creatine kinase is not due to beta 2-adrenoceptor partial agonist activity. Br J Clin Pharmacol. 1991 Jun;31(6):723-4. [PubMed:1678274 ]
  4. Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77. [PubMed:1687398 ]
  5. Doggrell SA: Relaxant and beta 2-adrenoceptor blocking activities of (+/- )-, (+)- and (-)-pindolol on the rat isolated aorta. J Pharm Pharmacol. 1990 Jun;42(6):444-6. [PubMed:1979630 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C: Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial. Neuropsychopharmacology. 1999 Apr;20(4):380-5. [PubMed:10088139 ]
  2. Haddjeri N, de Montigny C, Blier P: Modulation of the firing activity of rat serotonin and noradrenaline neurons by (+/-)pindolol. Biol Psychiatry. 1999 May 1;45(9):1163-9. [PubMed:10331108 ]
  3. Gobert A, Millan MJ: Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors. Neuropsychopharmacology. 1999 Aug;21(2):268-84. [PubMed:10432475 ]
  4. Andree B, Thorberg SO, Halldin C, Farde L: Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl). 1999 Jun;144(3):303-5. [PubMed:10435400 ]
  5. Fornal CA, Martin FJ, Metzler CW, Jacobs BL: Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats. J Pharmacol Exp Ther. 1999 Oct;291(1):229-38. [PubMed:10490909 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Dawson LA, Nguyen HQ: The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. Neuropharmacology. 2000 Apr 3;39(6):1044-52. [PubMed:10727715 ]
  2. Ariani K, Hamblin MW, Tan GL, Stratford CA, Ciaranello RD: G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes. Neurochem Res. 1989 Sep;14(9):835-43. [PubMed:2512511 ]
  3. Leonhardt S, Herrick-Davis K, Titeler M: Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. J Neurochem. 1989 Aug;53(2):465-71. [PubMed:2664084 ]
  4. Herrick-Davis K, Titeler M, Leonhardt S, Struble R, Price D: Serotonin 5-HT1D receptors in human prefrontal cortex and caudate: interaction with a GTP binding protein. J Neurochem. 1988 Dec;51(6):1906-12. [PubMed:3141589 ]
  5. Terron JA, Lopez-Munoz FJ, Hong E, Villalon CM: 2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery. Arch Int Pharmacodyn Ther. 1994 Jan-Feb;327(1):56-68. [PubMed:7944828 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23